Antares Pharma, Inc. (ATRS)

[jab91252]

Some more thoughts on this PFE/AIS deal:

The market(s) take on the pps of AIS, imo, seems to be never in line with our expectations. But another deal with the likes of PFE will most likely be a future driver and there's the rub I believe.....'most likely' a future driver. We hope it is, but we just don't know given lack of the intimate details and that slippery slope to the future.

That limitation on the royalties is both interesting and curious...." royalties on net sales for three years post launch in the US"....an existing PFE product(?).

Also given this statement prior to the royalty info its noted: "Pfizer will assume full cost and responsibility for all clinical development, manufacturing, and commercialization of the product in the licensed territory, which also includes certain non-exclusive territories outside of North America"......
perhaps the 3 yr royalty post launch in the US while signifying a time end date certain, does not privy us to a potential global transition deal to territories outside the US. Meaning, 3yrs, let us see where this goes and if the numbers and market is there - we take it to the next level - tranche two.

"Non-exclusive" to whom? Could Antares have cut a deal outside the US, in that PFE will assume that full cost for those territories while Antares takes the lead role?

3 yr royalty limit???? Could this correspond to an approximate date of an existing PFE product patent expiration?

This is interesting.